ArticleLeukemia2022

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.

Elise Fournier et al.PubMed ↗Publisher ↗

No numbers read from the abstract.